文章摘要

文章信息/Info

Title:: The Leptin ParadoxA Treacherous Art in cardiac sequelae of obesity

作者:: 任骏

Author(s):: REN Jun; Department of Physiology, Fourth Military Medical University, Xi’an 710032, Shaanxi, China; Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071, USA

关键词:: -

Keywords:: leptin; leptin resistance; obesity; heart disease

分类号:: -

DOI:: -

文献标识码:: -

摘要:: -

Abstract:: Leptin is the first identified obese gene product which participates in the regulation of food intake, energy expenditure, glucose and lipid metabolism. Leptin initiates both hypertrophic and antihypertrophic effects on hearts in addition to its cardiac depressant effect. Circulating leptin levels correlate with the body mass index (BMI) and total amount of body fat, which may be associated with changes of cardiac morphology and function. It has been shown that cardiac function is present in both hyperleptinemic (db/db) and hypoleptinemic (ob/ob) mouse models. Leptin replenishment reconciles the compromised myocardial function in ob/ob mice, indicating the premises of leptin on heart function. Interestingly, elevated plasma leptin levels may trigger leptin resistance and serve as an independent risk factor for cardiovascular diseases. Therefore, physiological range of leptin is essential for normal cardiac geometry and function whereas disrupted leptin signaling (hyper-and hypoleptinemia) results in functional and morphological aberrations leading to heart problem. Given that human obesity is a syndrome of leptin resistance, which is unlikely amenable to leptin treatment, the identification of novel parallel signal transduction pathways is of particular therapeutic value for obesityassociated cardiac dysfunction.

参考文献/References

[1］ Gardner M, Gardner DW, Sowers JR. The cardiometabolic syndrome in the adolescent［J］. Pediatr Endocrinol Rev, 2008, 5(Suppl 4):964-968.
［2］ Sowers JR. Obesity as a cardiovascular risk factor［J］. Am J Med, 2003, 115(Suppl 8A):37S-41S.
［3］ Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood InstituteNational Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesityassociated cardiovascular disease［J］. Circulation, 2002, 105(24):2923-2928.
［4］ Ren J, Sowers JR, Walsh MF, et al. Reduced contractile response to insulin and IGFI in ventricular myocytes from genetically obese Zucker rats［J］. Am J Physiol Heart Circ Physiol, 2000, 279(4):H1708-H1714.
［5］ Sowers JR. Obesity and cardiovascular disease［J］. Clin Chem, 1998, 44(8 Pt 2):1821-1825.
［6］ Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks［J］. Science, 1995, 269(5223):546-549.
[7］ Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene［J］. Diabetes, 1996, 45(11):1455-1462.
［8］ Friedman JM. The function of leptin in nutrition, weight, and physiology［J］. Nutr Rev, 2002, 60(10 Pt 2):S1-S14.
［9］ Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product［J］. Nature, 1995, 377(6549):530-532.
［10］Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake［J］. Nature, 2000, 404(6778):661-671.
［11］Shimokawa I, Higami Y. Leptin signaling and aging: insight from caloric restriction［J］. Mech Ageing Dev, 2001, 122(14):1511-1519.
［12］Ross SA, Gulve EA, Wang M. Chemistry and biochemistry of type 2 diabetes［J］. Chem Rev, 2004, 104(3):1255-1282.
［13］Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathwaya link between adipose tissue mass and central neural networks［J］. Horm Metab Res, 1996, 28(12):619-632.
［14］Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults［J］. Proc Natl Acad Sci USA, 2004, 101(13):4531-4536.
［15］Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactiveleptin concentrations in normalweight and obese humans［J］. N Engl J Med, 1996, 334(5):292-295.
［16］Tartaglia LA. The leptin receptor［J］. J Biol Chem, 1997, 272(10):6093-6096.
［17］Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OBR［J］. Cell, 1995, 83(7):1263-1271.
［18］Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin［J］. Science, 1996,274(5290):1185-1188.
［19］Kotajima N, Takahashi T, Ito H, et al. Clinical features associated with circulating concentration of soluble leptin receptor in patients with diabetes［J］. J Int Med Res, 2005, 33(1):61-67.
［20］Zabeau L, Lavens D, Peelman F, et al. The ins and outs of leptin receptor activation［J］. FEBS Lett, 2003, 546(1):45-50.
［21］Bjorbaek C, ElHaschimi K, Frantz JD, et al. The role of SOCS-3 in leptin signaling and leptin resistance［J］. J Biol Chem, 1999, 274(42):30059-30065.
［22］Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease［J］. Curr Opin Nephrol Hypertens, 2004, 13(2):215-223.
［23］Artham SM, Lavie CJ, Milani RV, et al. The obesity paradox: impact of obesity on the prevalence and prognosis of cardiovascular diseases［J］. Postgrad Med, 2008, 120(2):34-41.
［24］Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin1reactive oxygen species pathway in cultured neonatal rat cardiomyocytes［J］. Circulation, 2004, 110(10):1269-1275.
［25］Shin HJ, Oh J, Kang SM, et al. Leptin induces hypertrophy via p38 mitogenactivated protein kinase in rat vascular smooth muscle cells［J］. Biochem Biophys Res Commun, 2005, 329(1):18-24.
［26］Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice［J］. Circulation, 2003, 108(6):754-759.
［27］Dong F, Zhang X, Yang X, et al. Impaired cardiac contractile function in ventricular myocytes from leptindeficient ob/ob obese mice［J］. J Endocrinol, 2006, 188(1):25-36.
［28］Raju SV, Zheng M, Schuleri KH, et al. Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptindeficient and leptinresistant obesity［J］. Proc Natl Acad Sci U S A, 2006, 103(11):4222-4227.
［29］Nickola MW, Wold LE, Colligan PB, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO［J］. Hypertension, 2000, 36(4):501-505.
［30］Dong F, Zhang X, Ren J. Leptin Regulates Cardiomyocyte Contractile Function Through Endothelin1 ReceptorNADPH Oxidase Pathway［J］. Hypertension, 2006, 47(2):222-229.
［31］Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart［J］. Diabetes, 2004, 53(12):3201-3208.
［32］Carley AN, Semeniuk LM, Shimoni Y, et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function［J］. Am J Physiol Endocrinol Metab, 2004, 286(3):E449-E455.
［33］Kanda T, Takahashi T, Kudo S, et al. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis［J］. Life Sci, 2004, 75(12):1435-1447.
［34］Minhas KM, Khan SA, Raju SV, et al. Leptin repletion restores depressed {beta}adrenergic contractility in ob/ob mice independently of cardiac hypertrophy［J］. J Physiol, 2005, 565(Pt 2):463-474.
［35］Winters B, Mo Z, BrooksAsplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice［J］. J Appl Physiol, 2000, 89(6):2382-2390.
［36］Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure［J］. Hypertension, 1998, 31(1 Pt 2):409-414.
［37］Ruige JB, Mertens I, Considine RV, et al. Opposite effects of insulinlike molecules and leptin in coronary heart disease of type 2 diabetes Preliminary data［J］. Int J Cardiol, 2006, 111(1):19-25.
［38］Dong F, Ren J. Fitness or fatnessthe debate continues for the role of leptin in obesityassociated heart dysfunction［J］. Curr Diabetes Rev, 2007, 3(3):159-164.
［39］Barouch LA, Gao D, Chen L, et al. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity［J］. Circ Res, 2006, 98(1):119-124.
［40］Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNFalpha［J］. Int J Cardiol, 2002, 83(1):73-81.
［41］Leyva F, Anker SD, Egerer K, et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin［J］. Eur Heart J, 1998 , 19(10):1547-1551.
［42］Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure［J］. Eur J Heart Fail, 2003, 5(1):33-40.
［43］Frankenberry KA, Somasundar P, McFadden DW, et al. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells［J］. Am J Surg, 2004, 188(5):560-565.
［44］Narkiewicz K, Somers VK, Mos L, et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension［J］. J Hypertens, 1999, 17(2):245-249.
［45］Winnicki M, Phillips BG, Accurso V, et al. Independent association between plasma leptin levels and heart rate in heart transplant recipients［J］. Circulation, 2001, 104(4):384-386.
［46］Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension［J］. Am J Hypertens, 1997, 10(10 Pt 1):1171-1174.
［47］Sderberg S, Ahrén B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction［J］. J Intern Med, 1999, 246(4):409-418.

我们的网站为什么显示成这样？

The Leptin ParadoxA Treacherous Art in cardiac sequelae of obesity

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics